Impact of Human Communication in a Multi-teacher, Multi-robot Learning by Demonstration System.

A wide range of architectures have been proposed within the areas of learning by demonstration and multi-robot coordination. These areas share a common issue: how humans and robots share information and knowledge among themselves. This paper analyses the impact of communication between human teachers during simultaneous demonstration of task execution in the novel Multi-robot Learning by Demonstration domain, using the MRLbD architecture. The performance is analysed in terms of time to task completion, as well as the quality of the multi-robot joint action plans. Participants with different levels of skills taught real robots solutions for a furniture moving task through teleoperation. The experimental results provided evidence that explicit communication between teachers does not necessarily reduce the time to complete a task, but contributes to the synchronisation of manoeuvres, thus enhancing the quality of the joint action plans generated by the MRLbD architecture

Initial Use of Endothelial Progenitor Cells Capturing Stents in Paediatric Congenital Heart Disease

INTRODUCTION: Stenosis, mediated by neointimal hyperplasia and thrombosis, is a major limiting factor in successful stent implantation. The introduction of a stent, coated in its endoluminal surface by antihuman CD34 antibodies with endothelial progenitor cell-capturing properties, opens the possibility of promoting a rapid and normal functioning coverage by endothelium and thus avoids both an excessive cell proliferation within stent and the need for long-term dual antiplatelet therapy. These stents, developed for adult coronary artery disease, have not yet been implanted in children or in those with congenital heart disease. OBJECTIVE AND METHODS: In this paper, we describe the implantation of Genous® stents in three children with cyanotic congenital heart disease and obstructed systemic-to-pulmonary shunts. We describe the use of this stent and address its potential feasibility in paediatric congenital heart disease. RESULTS: To maintain the patency of two modified Blalock-Taussig shunts and one ductus arteriosus, four Genous® stents were implanted in three infants with cyanotic heart disease. All procedures were immediately successful, with resolution of stenosis and improvement in transcutaneous oxygen saturation from 66% ± 3.6% to 92% ± 2.6%. In the follow-up, one stent had no occlusion; however, the remaining two had partial occlusion after 5 and 5.5 months, which were successfully managed with balloon dilatation preceding elective definitive surgical correction. CONCLUSION: In our preliminary experience, we demonstrated that Genous® stent implantation was feasible in infants with complex congenital heart disease. Additional studies with larger samples and longer follow-up are required to confirm the potential benefits of this technology in this clinical setting.info:eu-repo/semantics/publishedVersio

Civil society and "third sector": embezzlement of the theoretical-political legacy of Gramsci

The present article discusses the emergency of the civil society as a key concept to comprehend the dynamics of the actual developmental phase of capitalism in Brazil and the process of restructuring the productivity and social relations. In search of the geneses identification of this concept, here it is presented its accepted contratualist, Hegelians and Marxists. However, the fundamental objective is to question the literature that some new social actors have done with this term, specifically those that self entitled themselves as members of the "third sector". Because many of these social subjects indebtely attempt to anchor in the theoretical-methodological and political gramscian and their idealist and liberal positions, equivocally taken as neutral by the ethical, political and ideological point of view.20267510

Influence of normal mammary epithelium on breast cancer progression: the protective role of early pregnancy

AIMS AND BACKGROUND: The microenvironment has a well recognized role in breast cancer progression. Despite different theories, the mechanism of early pregnancy protection in mammary carcinogenesis is unknown. Since pregnancy is responsible for mammary gland differentiation, we tested the hypothesis that differentiated mammary epithelial cells may inhibit breast cancer progression. In other words, the protective role of early pregnancy could be due to the inhibitory influences of the more differentiated mammary tissue. METHODS: In order to test our hypothesis, we used 30 female Balb/c nude mice and MCF-7 cells of breast adenocarcinoma. The female mice were divided into two test groups, group I (GI) and group II (GII), and a control group. In GII, the animals were submitted to epithelial removal in the left fourth inguinal mammary gland at 3 weeks of age. Both groups were given continuous hormonal treatment to simulate the pregnancy development of the mammary gland. Two million MCF-7 cells were then injected into the fourth inguinal mammary gland (GI) or in the respective cleared mammary fat pad (GII). Five weeks later the mice were sacrificed and their tumors removed. Tumor development rates and tumor volumes were determined and proliferation and apoptosis were evaluated by immunohistochemistry. RESULTS: Tumors of GII mice had a larger mean volume than those of GI mice (P = 0.001, Mann-Whitney U-test) and an apparent increase in proliferation, demonstrated by a higher staining intensity for proliferating cell nuclear antigen (PCNA). As tumors presented caspase 8 staining, there may be apoptotic activation involved in cell death, mainly through an extrinsic pathway. CONCLUSIONS: These results suggest that a differentiated intact mammary gland may have an inhibitory influence on mammary tumor growth in mice

Exercise-Induced Intraventricular Obstruction in a Child with Near Syncope and Chest Pain During Exercise

We report the case of a 10-year-old girl with two episodes of light-headedness and chest pain during exercise. She had an unremarkable clinical record, physical examination, ECG, and echocardiogram. Noninvasive ischemia tests were positive, but coronary angiography was normal. Exercise stress echocardiogram revealed an exercise-induced intra-left-ventricular obstruction with a peak gradient of 78 mmHg and replicated her symptoms. After starting beta-blocker therapy her clinical status improved and no residual obstruction was detected. The authors review this unsuspected clinical condition, seldom reported in the adult population and, to our knowledge, never before in a child

Tuning the transport gap of functionalized graphene via electron beam irradiation

We demonstrate a novel method to tune the energy gap epsilon1 between the localized states and the mobility edge of the valence band in chemically functionalized graphene by changing the coverage of fluorine adatoms via electron-beam irradiation. From the temperature dependence of the electrical transport properties we show that epsilon1 in partially fluorinated graphene CF0.28 decreases upon electron irradiation up to a dose of 0.08 C cm−2. For low irradiation doses (0.2 C cm−2) the electrical conduction takes place via Mott variable range hopping.SR and MFC acknowledge financial support from EPSRC (grant numbers EP/G036101/1, EP/J000396/1, EP/K017160/1 and EP/K010050/1). SR acknowledges financial support from the Royal Society Research grant number 2010/R2 (grant number SH-05052)

Caracterização da Utilização de Sugamadex no Centro Hospitalar de Lisboa Central - Hospital de S. José

Introdução O sugamadex é uma gama ciclodextrina modificada que forma um complexo com os bloqueadores neuromusculares rocurónio e vecurónio, revertendo o bloqueio neuromuscular (BNM) induzido por estes fármacos1,2,3,4. O sugamadex apresentou valor terapêutico acrescentado em relação aos anticolinesterásicos, nomeadamente à neostigmina, para a reversão do BNM causado pelo rocurónio e vecurónio1,3. No Hospital de São José (HSJ) este medicamento foi introduzido em Outubro de 2010 para a reversão do BNM profundo e nas situações de risco de vida imediato associadas a via aérea difícil com impossibilidade de ventilar e de entubar. A dispensa do sugamadex é efectuada por reposição de stock mediante envio de justificação clínica aos Serviços Farmacêuticos (SF). Objetivo Caracterizar a utilização de sugamadex no HSJ: evolução do consumo, serviços clínicos utilizadores e adequação da utilização clínica face às indicações aprovadas pela Comissão de Farmácia e Terapêutica (CFT). Métodos Pesquisa e análise bibliográfica. Recolha, através da do sistema de gestão integrada do circuito do medicamento, dos dados de consumo desde Outubro de 2010 até Junho de 2015, por semestre e por serviço clínico. Recolha das indicações terapêuticas em que o sugamadex foi administrado, no período acima referido, através da consulta das justificações clínicas. Análise retrospectiva dos dados recolhidos. Resultados Apresentação gráfica dos consumos de sugamadex nos serviços utilizadores no período em estudo. Apresentação gráfica das indicações terapêuticas em que foi administrado, por serviço e no período em estudo. Conclusões O consumo de sugamadex tem um evidente crescimento desde o seu início de utilização. A justificação dominante para a utilização do sugamadex é a curarização residual. Verifica-se um alargamento do âmbito de utilização, face às indicações aprovadas pela CFT. Decorridos cinco anos de utilização, justifica-se uma reavaliação das indicações de utilização no HSJ pela CFT. Bibliografia 1. Chambers D, Paulden M, Paton F, Heirs M, Duffy S, Craig D, et al. Sugammadex for the reversal of muscle relaxation in general anaesthesia: a systematic review and economic assessment. Health Technol Assess 2010;14(39). 2. De Boer HD, Van Egmond J, Driessen JJ, Booij LH. Update on the management of neuromuscular block: Focus on sugammadex. Neuropsychiatr Dis Treat 2007;3:539-44. 3. Relatório avaliação prévia de medicamento para uso humano em meio hospitalar – DCI – Sugamadex (06-05-2010) – Infarmed - acedido a 27/08/2015 www.infarmed.pt. 4. Resumo das Características do Medicamento Bridion® 100 mg/ml solução injectável - acedido a 27/08/2015 www.ema.europa.eu/